CD19 and cancer: Secondary malignant neoplasms are currently in the spotlight after the FDA announced a boxed warning for BCMA (B-cell maturation antigen)–directed and CD19-directed autologous CAR T-cell therapy.18 This announcement was based on 22 cases of secondary malignant neoplasms diagnosed, with a latency period ranging from 1 to 19 months (50% occurring in the first year after infusion).40,41,42,43,44 In our study, with prospective epidemiologic surveillance covering the incidence period reported by the FDA, we did not identify any cases of T-cell malignant neoplasms.